Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study

234Citations
Citations of this article
232Readers
Mendeley users who have this article in their library.

Abstract

Background - Inflammatory processes have been identified as key mediators of the deleterious effects of ischemia/reperfusion in ST-segment-elevation myocardial infarction. Colchicine is a substance with potent anti-inflammatory properties, suitable for safe use in patients with cardiovascular disease. The purpose of this study was to test the hypothesis that a short course of colchicine treatment could lead to reduced infarct size. Methods and Results - Patients presenting with ST-segment-elevation myocardial infarction ≤12 hours from pain onset (treated with primary percutaneous coronary intervention) were randomly assigned to colchicine or placebo for 5 days. The primary outcome parameter was the area under the curve of creatine kinase-myocardial brain fraction concentration. A subset of patients underwent cardiac MRI with late gadolinium enhancement 6 to 9 days after the index ST-segment-elevation myocardial infarction. One hundred fifty-one patients were included (60 in the MRI substudy). The area under the creatine kinase-myocardial brain fraction curve was 3144 (interquartile range [IQR], 1754-6940) ng·h-1·mL-1 in the colchicine group in comparison with 6184 (IQR, 4456-6980) ng·h-1·mL-1 in controls (P<0.001). Indexed MRI-late gadolinium enhancement-defined infarct size was 18.3 (IQR, 7.6-29.9) mL/1.73 m2 in the colchicine group versus 23.2 (18.5-33.4) mL/1.73 m2 in controls (P=0.019). The relative infarct size (as a proportion to left ventricular myocardial volume) was 13.0 (IQR, 8.0-25.3) % and 19.8 (IQR, 13.7-29.8) %, respectively (P=0.034). Conclusions - These results suggest a potential benefit of colchicine in ST-segment-elevation myocardial infarction, but further clinical trials are necessary to draw secure conclusions, especially considering the fact that the present study was not powered to assess clinical end points. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT01936285.

References Powered by Scopus

Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain

1446Citations
N/AReaders
Get full text

Atherosclerosis is an inflammatory disease

1231Citations
N/AReaders
Get full text

Myocardial reperfusion: A double-edged sword?

1213Citations
N/AReaders
Get full text

Cited by Powered by Scopus

From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection

731Citations
N/AReaders
Get full text

The NLRP3 inflammasome in acute myocardial infarction

501Citations
N/AReaders
Get full text

Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease

494Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Deftereos, S., Giannopoulos, G., Angelidis, C., Alexopoulos, N., Filippatos, G., Papoutsidakis, N., … Lekakis, J. (2015). Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study. Circulation, 132(15), 1395–1403. https://doi.org/10.1161/CIRCULATIONAHA.115.017611

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 54

49%

Researcher 37

33%

Professor / Associate Prof. 15

14%

Lecturer / Post doc 5

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 94

77%

Biochemistry, Genetics and Molecular Bi... 16

13%

Nursing and Health Professions 6

5%

Agricultural and Biological Sciences 6

5%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free